Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 40 of the 56 sources its claims cite were checked for support.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have been approved to target obesity-related heart failure with preserved ejection fraction. METHODS: We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The dual primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in the 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level. RESULTS: The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001), and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001). The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001). In the analysis of the hierarchical composite end point, semaglutide produced more wins than placebo (win ratio, 1.72; 95% CI, 1.37 to 2.15; P<0.001). The mean percentage change in the CRP level was -43.5% with semaglutide and -7.3% with placebo (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). Serious adverse events were reported in 35 participants (13.3%) in the semaglutide group and 71 (26.7%) in the placebo group. CONCLUSIONS: In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).
Overview
CoChat Summary
TL;DR
In STEP-HFpEF, once-weekly semaglutide 2.4 mg versus placebo in patients with heart failure with preserved ejection fraction and obesity improved heart failure symptoms/physical limitations, body weight, exercise function, a hierarchical composite outcome, and CRP over 52 weeks. Semaglutide also had fewer serious adverse events than placebo.
Key findings
- Dual primary end points: mean KCCQ-CSS change was 16.6 points with semaglutide vs 8.7 with placebo (estimated difference, 7.8 points; 95% CI, 4.8 to 10.9; P<0.001), and mean body weight changed by -13.3% vs -2.6% (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).
- Confirmatory secondary end points: 6-minute walk distance changed by 21.5 m vs 1.2 m (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001); hierarchical composite win ratio was 1.72 (95% CI, 1.37 to 2.15; P<0.001); CRP changed by -43.5% vs -7.3% (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001).
- Safety: serious adverse events occurred in 35 participants (13.3%) with semaglutide vs 71 (26.7%) with placebo (P<0.001), driven mainly by fewer cardiac disorder events (7 [2.7%] vs 30 [11.3%]; P<0.001); discontinuation due to any adverse event occurred in 35 vs 14 participants, predominantly gastrointestinal events.
- Exploratory: adjudicated heart failure hospitalization or urgent visit occurred in 1 semaglutide participant vs 12 placebo participants (hazard ratio, 0.08; 95% CI, 0.00 to 0.42).
Methods
- Randomized, double-blind, placebo-controlled trial at 96 sites in 13 countries; 529 participants with HFpEF, BMI ≥30, LVEF ≥45%, NYHA class II–IV, KCCQ-CSS <90, and 6-minute walk distance ≥100 m were assigned 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks plus 5-week follow-up.
- Dual primary end points were change in KCCQ-CSS and percentage change in body weight at week 52; confirmatory secondary end points included 6-minute walk distance, a hierarchical composite (death, heart failure events, KCCQ-CSS and 6-minute walk differences), and CRP.
- Efficacy was analyzed in the full analysis population using the treatment policy estimand; continuous end points used ANCOVA, the hierarchical composite used a win-ratio approach, and safety was analyzed in the as-treated safety population.
Limitations
- Stated in the paper: the number of non-White participants was low, which may limit generalizability; the trial was not adequately powered for clinical events such as heart failure hospitalizations/urgent visits; follow-up was limited to 1 year; specific glycated hemoglobin data were not collected beyond excluding diabetes; and SGLT2 inhibitor use was low.
- Evident from the text: the trial population was 95.8% White, median age 69 years, all with BMI ≥30, and patients with diabetes were excluded, so findings may not generalize to more diverse, younger, non-obese, or diabetes populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 90 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that obesity and excess adiposity are not simply coexisting conditions but may play a role in the development and progression of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Background calls obesity a risk factor for incident heart failure, and the Discussion links severe obesity to more adverse outcomes and hospitalizations among patients who already have HFPEF. These findings support the hedged suggestion that obesity may matter beyond coexistence, but the paper does not establish a role for excess adiposity specifically in the development or progression of HFPEF; its HFPEF analysis concerns BMI and outcomes. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. source
The Discussion (page not provided) states that increased adiposity promotes conditions that contribute to HFpEF pathophysiology. The Conclusions (page not provided) add that adipose deposition may have adverse consequences for HFpEF. Together, these support the citing sentence’s hedged claim that adiposity may play a role rather than merely coexist with the disease. (LLM, conf=0.88)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The main text explicitly says that excess adipose tissue likely plays a pivotal role in the development and progression of HFpEF. It also describes evidence linking adiposity to incident HFpEF and adverse outcomes in established HFpEF. This supports the citing sentence’s hedged claim that obesity and excess adiposity may contribute rather than merely coexist. (LLM, conf=0.94)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5 describes obesity-related changes that can lead to HFpEF. Section 5.8.1 links visceral adiposity to the risk of developing HFpEF and reports that central adiposity is associated with worse outcomes in patients who have it. Together, these passages support the hedged claim that excess adiposity may contribute to development and progression. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that adipose tissue may play a pivotal role in the development, progression, and adverse outcomes of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a U-shaped association between BMI and adverse outcomes in patients with HFpEF, and the paper describes obesity as a risk factor for developing heart failure generally. It does not establish a role for adipose tissue in HFpEF progression or specifically in its development; BMI is not a direct measure of adipose-tissue activity. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Partly supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says increased adiposity contributes to HFpEF pathophysiology and links abdominal fat to impaired exercise tolerance in older obese patients. This supports a possible role for adipose tissue, but the paper does not establish its role in HFpEF progression or in adverse clinical outcomes. (LLM, conf=0.85)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The paper’s main text explicitly says that excess adipose tissue likely plays a pivotal role in HFpEF development, progression, and adverse outcomes. It also identifies visceral adipose tissue as especially important in metabolic/obese HFpEF. (LLM, conf=0.95)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5.8.1 (page not provided) describes a pivotal role for visceral adipose tissue in obese HFpEF, linking it to both incident HFpEF risk and worse outcomes. Section 5.3 (page not provided) describes mechanisms by which epicardial adipose tissue may impair cardiac function and reports associations with greater disease severity and hospitalization or death. Together, these passages support the claim’s hedged wording. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Even when patients have well compensated heart failure with preserved ejection fraction and are in stable condition, they have markedly impaired objectively measured physical function. 34”
What the sources say
- Partly supportedcites [34] 34. Pandey A, Shah SJ, Butler J, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol 2021; 78: 1166-87. sourceExperimental — accuracy not yet measured
In ‘EI: A Key Manifestation of HFpEF’ (page unavailable), the review reports that objectively measured peak oxygen uptake is, on average, 35% lower in patients with HFpEF than in matched healthy controls. This supports marked impairment, but the passage does not establish that the patients were well-compensated and clinically stable. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our findings of substantial reductions in symptoms and physical limitations and improvements in exercise function that parallel a greater degree of weight loss with semaglutide than with placebo may offer insights into the long-standing controversy surrounding weight (and weight loss) in persons with heart failure. 8”
What the sources say
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“previous global clinical trial programs of agents such as SGLT2 inhibitors, sacubitrilvalsartan, and spironolactone for heart failure with preserved ejection fraction showed only modest changes in KCCQ scores (ranging from 0.5 to 2.3 points). 31-33”
What the sources say
- Partly supportedcites [31] 31. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation 2022; 145: 184-93. sourceExperimental — accuracy not yet measured
The Discussion (page not available) reports modest KCCQ improvements in the TOPCAT spironolactone and PARAGON-HF sacubitril/valsartan trials, while the Results report modest improvements with the SGLT2 inhibitor empagliflozin. These passages support the overall characterization, but they do not establish the stated range of 0.5 to 2.3 points. (LLM, conf=0.86)
- Partly supportedcites [32] 32. Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of dapagliflozin on health status inpatients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol 2023; 81: 460-73. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes the KCCQ benefit with dapagliflozin in DELIVER as modestly higher than that with empagliflozin in EMPEROR-PRESERVED, and mentions the sacubitril-valsartan PARAGON-HF trial. It does not establish the claimed 0.5–2.3-point range across those trials or report a corresponding spironolactone result. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [33] 33. Lewis EF, Kim HY, Claggett B, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2016; 9(3): e001937. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
45 more claims · 1 with their cited sources checked
Create a free account to see all 113 claims and every source verdict.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 43
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and there is evidence that semaglutide 2.4 mg improves heart failure with preserved ejection fraction in individuals without diabetes by a potentially direct or indirect effect on epicardial adipose tissue (Kosiborod et al, 2023;Myasoedova et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Kosiborod et al, 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with HFpEF and obesity (with and without diabetes), semaglutide 2.4 mg once weekly for 52 weeks improved symptoms, physical function, exercise function and bodyweight compared to placebo (STEP HFpEF and STEP HFpEF DM clinical trials) [59,91].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the STEP-HFpEF trial, semaglutide treatment in patients with obesity-related HFpEF led to significant improvements in the 6-min walk distance (6MWD) and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), despite concurrent losses in lean mass [38].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“weight-loss interventions (eg, gastric bypass surgery and glucagon-like peptide-1 receptor agonists) can reduce the risk of incident HF and improve symptoms in patients with established HFpEF.16–20”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
39 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationO'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Self-citationHeart Failure With Preserved, Borderline, and Reduced Ejection Fraction
Shah, K. S., Xu, H., Matsouaka, R. A., Bhatt, D. L., Heidenreich, P. A., Hernandez, A. F., Devore, A. D., Yancy, C. W., & Fonarow, G. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.074 · Cited by 1,110
Epidemiology of Heart Failure: A Contemporary Perspective
Roger, V. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318172 · Cited by 946
Kitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016) · JAMA · doi:10.1001/jama.2015.17346 · Cited by 921
Self-citationBordicchia, M., Liu, D., Amri, E.-Z., Ailhaud, G., Dessì-Fulgheri, P., Zhang, C., Takahashi, N., Sarzani, R., & Collins, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59701 · Cited by 872
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationEvaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Self-citation
Cited by
Items 1,301–1,400 of 1,639
Stoichescu-Hogea, G., Craciun, M.-L., Pah, A.-M., Avram, A. C., Rada, M., Otiman, G., Jupaneant, C., Ples, C., Mahmoud, A., & Dragan, S. R. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187096 · Cited by 1
Almahmeed, W. A., Barajas-Gamboa, J. S., Zubaid, M., Al‐Ozairi, E., Shehab, A., Al‐Rasadi, K., Khalil, C. A., Busaidi, N. A., Sindi, F. A., Awan, Z. A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70204
Upadhyay, N., Batra, K., Le, L., Steffens, A., Carlyle, M., Song, R., Horstman, T., Ye, W., & Plat, A. W. (2026) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2026.101939
Öztürk, C. (2024) · CardioVasc · doi:10.1007/s15027-024-3623-y
Effects of metabolic syndrome on cardiovascular outcomes in non-obese heart failure patients
Han, D. D., Miedlich, S. U., Morse, D. S., Block, R. C., Zaręba, W., Goldenberg, I., McNitt, S. A., & Kutyifa, V. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag073
“…which improves glucose, blood pressure con-trol, dyslipidaemia as well as LV function has been shown to reduce progression and symptoms of HF. 14,15 For example, the SELECT trial showed that semaglutide, a glucagon-like peptide 1 receptor (GLP1R) agonist, reduced the risk for CV and composite…”
Recent Progression of Incretin-Based Obesity Treatment
Choi, D. (2024) · Korean Journal of Medicine · doi:10.3904/kjm.2024.99.2.78
He, J., Wei, J., Wang, B., Ru-fei, L., Wang, W., & Li, Y. (2026) · Biomolecules · doi:10.3390/biom16070989 · Cited by 1
“Semaglutide has been approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and tirzepatide has shown beneficial effects in patients with obesity-related heart failure with preserved ejection fraction [11,12].”
Improving the Analysis of KCCQ Endpoints in Heart Failure Clinical Trials
Myte, R., Eriksson, J., Rensfeldt, M., Jiang, Y., Al‐Shurbaji, A., & Nyström, P. O. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00888-7
“Interestingly, in two recent HF trials—the FINEART-HF and STEP-HFpEF trials [ 11, 12 ]—while the main KCCQ analyses were conducted traditionally using overall means, Estimates represent means for change from baseline and differences in the same between treatment groups for the comparison derived…”
Howie, J. O., Dziano, J. K., Ariyaratnam, J., Emami, M., Evans, S., Middeldorp, M. E., Puvrez, A., Kenny, G., Sanders, P., & Elliott, A. D. (2026) · Heart Rhythm O2 · doi:10.1016/j.hroo.2026.07.006
Disparities in access to pharmacotherapies for weight loss and cardiovascular prevention
Duell, P. B., & Maki, K. C. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.08.001
Research Progress of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Heart Failure
胡, 明. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1571991
Heart Failure With Preserved Ejection Fraction
Weigel, F., & Miller, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00188-6
Biegus, J. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag131
Gorban, V. V., Витальевна, Г. Е., & Kocherga, P. E. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-194
Chen, Z., Yang, Q., Liu, J. S., Zhao, H., Ying, H., Liu, H., Huang, L., Lin, H. Y., Wang, S., Li, M., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04888-8
“While a 52-weeks RCT showing that treatment with semaglutide relieved symptoms and physical limitations in patients with HFpEF [68], some other studies have explored the association between GLP-1R agonists and the core phenotype of HFpEF - left ventricular ejection fraction, but reported distinct…”
Abedi, M. M., Alabid, I., Alghoul, W. I. I., Salama, R. A. A., Lami, K. A. H. A., Marzougui, H., Swalha, B. R. R., Shaikh, S. A., Khan, S. S., & Mohamed, N. A. E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103767
Breakthrough drugs in the treatment of hypertension-related disease
Hoshide, S., Mogi, M., Shibata, S., Kishi, T., Usui, I., Ando, H., Nakagami, H., Nishiyama, A., Kario, K., & Japanese Society of Hypertension (JSH) Working Group on Emerging Pharmacological Therapies for Hypertension Management (2026) · Hypertension Research · doi:10.1038/s41440-026-02725-2
Tatekoshi, Y., Chen, C., Shapiro, J. S., Chang, H., Blancard, M., Lyra‐Leite, D. M., Burridge, P. W., Feinstein, M. J., D’Aquila, R. T., Hsue, P. Y., et al. (2024) · eLife · doi:10.7554/elife.95867.2
Hönemann, J., & Jordan, J. (2024) · Hypertension Research · doi:10.1038/s41440-023-01560-z
“Yet, a recent clinical trial showed that patients with heart failure and pre-served ejection fraction bene fi t from pharmacological weight loss through treatment with the glucagon-like peptide 1 receptor agonist (GLP1-RA) semaglutide [5].”
BackgroundSchulz, A., Kuttenkeuler, L., Backhaus, S. J., Lange, T., Otto, J., Gronwald, J., Evertz, R., Kowallick, J. T., Hasenfuss, G. P., & Schuster, A. (2025) · European Heart Journal - Imaging Methods and Practice · doi:10.1093/ehjimp/qyaf077 · Cited by 1
Highlights of the Most Recent American Diabetes Association Guidelines: From Evidence to Practice
Kim, M. K. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2329
“In patients with HF with preserved ejection fraction (HFpEF) and obesity, semaglutide (2.4 mg) has demonstrated significantly greater reductions in symptoms and physical limitations, improved exercise capacity, and enhanced weight loss compared with placebo [4].”
InfluentialNasir, L., Jalal, L., Siddiqa, A., Nasir, A., Farooqui, M., & Siddiqui, A. H. (2025) · European Journal of Therapeutics · doi:10.58600/eurjther2817
“Additionally, a study by Kosiborod et al. [13] demonstrated an increase in six-minute walk distance in patients taking semaglutide, further highlighting its role in enhancing physical activity.”
Obesity and heart failure—the role of GLP-1 receptor agonists
Simonis, G., & Schatz, U. (2025) · Herz · doi:10.1007/s00059-025-05312-2
Almeida-Alvarado, M. P., Solís, D. A. C., Mayorga, O. R. L., & Ávila, J. D. B. (2026) · Atlas Research Journal · doi:10.65305/arj.v4n1.2026.84
Li, J., Chen, Q., & Xu, Y. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04450-3
“The Kansas City Car-diomyopathy Questionnaire (KCCQ), a widely used PROs measure in heart failure, is primarily employed as a clinical endpoint to assess the efficacy of new drugs and to predict patient prognosis based on score changes [4, 5].”
Recent advances in the pharmacological treatment of obesity
Nam, G. E. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0058 · Cited by 1
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight lossPreprint
Murugadoss, K., Venkatakrishnan, A., Gregg, C. J., & Soundararajan, V. (2026) · Research Square · doi:10.21203/rs.3.rs-9407045/v1
Liu, M., Liu, H., Kim, E., Kang, G.-J., Neumann, M. C., Johnson, M., Murikinati, R., & Dudley, S. C. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101698
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss
Murugadoss, K., Venkatakrishnan, A., Gregg, C. J., & Soundararajan, V. (2026) · npj Cardiovascular Health · doi:10.1038/s44325-026-00146-1 · Cited by 3
“In the STEP-HFpEF trial which studied patients with heart failure with preserved ejection fraction (HFpEF) and obesity, the same dosing regimen signi fi cantlyreducedheartfailuresymptomsandimprovedexercisetolerance 2 .”
InfluentialBelančić, A., Majanović, S. K., Skroče, K., Ciudin, A., & Borovac, J. A. (2026) · Medicina · doi:10.3390/medicina62081446
Vafeidou, K., Koufakis, T., Stavropoulos, K., Zarfeiadou, M., Doumas, M. N., & Patoulias, D. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2634086
“The STEP-HFpEF trial demonstrated that subcutaneous semaglutide reduced symptoms, improved physical function and exercise capacity compared with placebo, and decreased the occurrence of serious adverse events among individuals with obesity and [11].”
Güvenç, T. S., Güvenç, R. Ç., Demir, G., Nikzad, M. T., & Ekmekçi, A. (2024) · Medical Hypotheses · doi:10.1016/j.mehy.2024.111298
Chen, S.-H., Lee, Y., Chuang, S., Fudim, M., Lee, C., Huang, C., & Cheng, H. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.049997 · Cited by 1
“Anti-inflammatory and weight-reducing interventions, such as semaglutide (as demonstrated in STEP-HFpEF 49 ) and sodium-glucose cotransporter-2 inhibitors, improve symptoms and cardiac outcomes in HFpEF, largely independent of glycemic control, but strongly linked to reductions in adiposity and inflammation.”
Skeletal Muscle in Heart Failure
Shah, A., Scheetz, S. D., & Baliga, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00183-7
Weight management in cardiology practice: challenges and opportunities
Leening, M. J. G., Martens, F. M. A. C., & Hemels, M. E. W. (2026) · Netherlands Heart Journal · doi:10.1007/s12471-026-02075-1
Ripoll, J. G., Herrera, H. R., Zaremba, S., Maruniak, S. R., Ursoleo, J. D., Wieruszewski, P. M., & Ramakrishna, H. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.08.160
Das, B. B. (2026) · Annals of Pediatric Cardiology · doi:10.4103/apc.apc_85_26
Ensuring the Appropriate Use of Glucagon‐Like Peptide‐1 Receptor Agonists
Moore, K. T., Gupta, A. S., Shen, J., & Kumar, P. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6136
Choi, H., & Hwang, A. Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70903
“…trials demonstrating meaningful improvements in symptoms and physical function in patients with HFpEF, obesity and/or type 2 diabetes, further supporting the role of incretin-based therapies not only in weight management but as an integral component of cardiovascular risk reduction [10, 11].”
Subclinical Diabetic Cardiomyopathy: Detectable but Not Yet Actionable
Tripathi, A. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.053346
Mechanism-driven therapy for diabetic cardiovascular disease
Sanchis‐Gomar, F., Lavie, C. J., Carbone, S., & Neeland, I. J. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.84
Myopenia in HFpEF: Impaired Muscle Quality Beyond the Heart
Pocai, A. (2026) · JCSM Communications · doi:10.1002/rco2.70048
Beyond phenogroups: towards a continuous biology of HFpEF
Störk, S., & Shimokawa, H. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag130
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
“In addition, the 6-min walk distance improved by 21.5 m compared to 1.2 m with placebo [47].”
InfluentialSztefka, D., Jaunich, A., Szlachetka, K., & Zając, A. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.5402
“…2.4 mg improved heart-failure-related symptoms and physical limitations assessed by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, increased 6-minute walk distance, and produced substantial weight loss in patients with obesity-related HFpEF (Kosiborod et al., 2023).”
InfluentialVenkataramanan, S. V. A. (2026) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2026.06.005
Ferreira, J. P., Zannad, F. M., & Solomon, S. D. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132278
IV CardioMIR: el Congreso de los Jóvenes Cardiólogos
Laffond, A. E., Borrego, J., Calle, D. G., & Guillén, P. L. C. (2023) · REC CardioClinics · doi:10.1016/j.rccl.2023.11.001
GLP-1 receptor agonism in cardiovascular disease prevention
Saleh, H. (2025) · Asia-Pacific Journal of Pharmacotherapy & Toxicology · doi:10.32948/ajpt.2024.11.22 · Cited by 1
Losordo, L. D., Amin, G., Singla, M., Belk, S. S., Butler, K. R., Booz, G. W., & Monafo, A. (2026) · Pediatric Research · doi:10.1038/s41390-026-05038-9
Kattamuri, L. P. V., Sharma, K., & Mukherjee, D. (2026) · International Journal of Angiology · doi:10.1055/a-2904-8847
“48,49 Tirzepatide extended this spectrum to obesity-related HFpEF with improved health status and fewer worsening hospitalizations for HF and cardiovascular death events.”
Self-citationDevice-based therapies for heart failure with preserved ejection fraction
Kim, R., Kittipibul, V., Bhatt, S., & Fudim, M. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10510-5 · Cited by 1
Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie
Busti, M. D., Canonico, M. E., Keramida, K., Palazzuoli, A., Kato, E. T., Sakata, Y., Alexy, T., Grupper, A., Nodari, S., Ojji, D. B., et al. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10627-1
Monami, M., Bertoli, S., Ciudin, A., McGowan, B. M., & Mannucci, E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70956 · Cited by 1
Cardiac-Adipose Axis in Heart Failure With Preserved Ejection Fraction
Tan, R., Ma, Y. X., Li, N., Zhou, Z., Huang, Z., Liu, T. L., Liao, H., Qin, X., Li, T., & Zhang, C. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.06.006
Loeb, S. A., Tharp, D. L., Zawieja, S. D., Pal, S., Abbate, A., & Isakson, B. E. (2026) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001844
“…cardiometabolic comorbidities (eg, hypertension, obesity, and type II diabetes) contribute to intrinsic diastolic dysfunction of the left ventricle — should be treated using SGLT2 inhibitors, 5,6 or, as of more recently, GLP-1 agonists, 7 which have been shown to improve patient clinical status.”
“The unbearable lightness” of the primary end point in clinical trials
Marian, A. J. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05098-7
New-Onset Heart Failure in Patients with Obesity using Tirzepatide or SemaglutidePreprint
Al-Nusair, M., Haddad, T. A., Khurana, S., & Al‐Nusair, J. (2026) · medRxiv · doi:10.64898/2026.09.21.26363546
Semaglutide in Atrial Arrhythmias: State of the Art and Future Perspectives
Maggio, E., Trivigno, S., Mariani, M. V., Piro, A., Pierucci, N., Vernile, A., Vinciullo, S., Palombi, M., Vizza, C. D., & Lavalle, C. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16100506
Advances in detection, prevention and treatment of heart failure in type 2 diabetes: part II
Cowley, A., Dattani, A., Brady, E. M., McCann, G. P., & Gulsin, G. S. (2024) · British Journal of Diabetes · doi:10.15277/bjd.2024.442
Integrating Hemodynamic Monitoring and Metabolic Therapy in Heart Failure
Falls, C. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.108978
Malmborg, M., El‐Chouli, M., Andersen, C. F., et al. (2025) · medRxiv · doi:10.1101/2025.05.05.25327040
Self-citationPrakash, S., Dhama, N., & Kumar, A. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10999-9
“However, these observations are strictly limited to preclinical animal experiments and have not been translated to the clinic yet [ 59 ].”
Ideta, M. M. L., Nihei, C. M. I., MOREIRA, P. H. B., & de Freitas, A. K. E. (2012) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20250043
Chattha, S. S., Kapadia, K., Lynch, D., & McWhorter, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1812235
Association of insulin and GH/IGF-1 derangements and heart failure: a narrative review
Cesaro, A., Calabrò, P., Ruvolo, A., & Fazio, S. (2026) · Exploration of Cardiology · doi:10.37349/ec.2026.101294
Improving Health Status With SGLT2 Inhibitors Following Worsening Heart Failure
Mentz, R. J., & Kittipibul, V. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.019
AlAraibi, A. J., Shakeeb, F. N., Alqatta, T., Sharafeldin, A.-B. K., Dempsey, L., & Butler, A. E. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104994
Hemdev, V., Abuzenah, M., Alsaafin, Q., Ghananeem, Z. A., Diksha, F., & Khatak, A. (2026) · Cureus · doi:10.7759/cureus.109953
Polhemus, D. J., Milstone, Z. J., & Hahn, V. S. (2026) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2026.05.009
Shokravi, A., Singh, R., Sharma, S., Seth, J., & Mancini, G. B. J. (2026) · CJC Open · doi:10.1016/j.cjco.2026.02.008 · Cited by 1
Hammer, Y., Arbel, R., Razi, T., Netzer, D., Weinstein, J. M., & Iakobishvili, Z. (2025) · Research Square · doi:10.21203/rs.3.rs-6768681/v1
Pedicino, D., & Volpe, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae427
Lau, L. C., Lui, T. W. D., Wen, C., Zhu, L., Lin, S., Leung, T. K. C., Luk, M. H., Ping Keung, C. H. A. N., Cheung, A., Chiu, K. Y., et al. (2026) · Bone & Joint Open · doi:10.1302/2633-1462.77.bjo-2025-0359.r1
“23,24 GLP-1RAs are therefore a plausible weight loss intervention to optimize TKA candidates, and their potential perioperative efects may extend beyond weight reduction alone and may include metabolic and anti-infam-matory mechanisms.”
EndoCompass Project: Research Roadmap for Diabetes, Obesity, and Metabolism
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., Beck, J., Chiarelli, F., León, D. D. D., et al. (2025) · Hormone Research in Paediatrics · doi:10.1159/000549194 · Cited by 1
“The dual GLP-1/GIP receptor agonist tirzepatide has shown convincing evidence for treating OSA in patients with obesity [88].”
Sunderland, N. P., Smith, M. L., McConnachie, A., Welsh, P. I., Taylor, R., Lean, M. E. J., Rogers, C. A., Blazeby, J. M., Sattar, N. A., Paternoster, L., et al. (2026) · PLoS Medicine · doi:10.1101/2025.11.14.25340254
Li, M. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1926629
“The consistent benefits observed in STEP-HFpEF and SUMMIT apply primarily to obesity-related HFpEF, whereas FIGHT and LIVE did not establish benefit in HFrEF and raised potential tolerability or safety concerns (10 – 18, 47, 48).”
InfluentialAlam, A. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_17_26
Semaglutide: The First Anti-Obesity Agent Shown to Decrease Cardiovascular Events
Mikhail, N. E., & Wali, S. (2024) · Annals of Cardiovascular Diseases · doi:10.47739/2641-7731.cardiovasculardiseases1036 · Cited by 1
Kardiovaskuläre Effekte von Semaglutid bei Patienten mit HFpEF und Adipositas
Dahm, J. B. (2024) · Kardiologie up2date · doi:10.1055/a-2327-3254
Ferreira, V. M. (2026) · Cureus · doi:10.7759/cureus.104817
“Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), supported by the STEP-HFpEF trial [9], may benefit patients with the obesity phenotype (BMI ≥30), though this is best conceptualized as obesity therapy with cardiovascular benefits rather than primary HF therapy, and cost constraints…”
HFpEF as a diabetic complication: the central role of microvascular dysfunction
Nagai, Y., Matoba, K., & Nishimura, R. (2026) · Discover Endocrinology and Metabolism · doi:10.1007/s44417-026-00023-6
“In the STEP-HFpEF trial, once-weekly semaglutide (2.4 mg) significantly improved HF-related symptoms (KCCQ-CSS), exercise capacity (6-minute walk distance), and inflammatory burden (CRP), alongside substantial weight reduction [57].”
InfluentialExploration of the Pathogenesis and Treatment of Heart Failure
Tumes, J. M., Ravishankar, A., Khan, I. H., Gonnah, A. R., & Roberts, D. H. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm49678 · Cited by 1
“The landmark STEP-HFpEF trial demonstrated that once-weekly semaglutide (2.4 mg) significantly improved heart failure related symptoms, physical limitations, and exercise capacity, along-side substantial weight reduction, in patients with obesity-related HFpEF [ 68,69].”
InfluentialCardiorenal Syndrome: Pathophysiology, Management, and the Challenge of Therapeutic Inertia
Gembillo, G., Calabrese, V., Soraci, L., Cicero, L. L., Scapellato, M., Messina, R., Ricca, M. F., Stancanelli, M. R., Corsonello, A., & Santoro, D. (2026) · Medicina · doi:10.3390/medicina62101855
Molecular insights in HIV-associated cardiac dysfunction
Valero‐Muñoz, M., Saw, E. L., Pimentel, D. R., Gower, A. C., Srinivasa, S., Zanni, M. V., Toribio, M. P., Grinspoon, S. K., & Sam, F. (2025) · Communications Medicine · doi:10.1038/s43856-025-01349-w · Cited by 1
McGuigan, A. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01154-4
Obesity Management and Cardiovascular Risk Reduction: from Tradition to Innovation
Costa, T. A., Harrington, J., Nelson, A. J., Pandey, A., Neeland, I. J., Lee, M. M. Y., Kang, Y. M., & McGuire, D. K. (2026) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-026-01138-1
Deaconu, L., Albai, O., Timar, B., Braha, A., Popescu, S., Sorescu, T., Gaiţă, L., Iordan, L., & Timar, R. Z. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124421
“In addition, among patients with obesity-related heart failure, treatment has been associated with improved functional status and increased exercise capacity (STEP-HFpEF) [31].”
Kurowski, M., Rekiel, K., Marcinkowska, A., Ratajczyk, O., Urbanowicz, P., Iwankiewicz, S., Grzelczak, W., & mierczak, Z. K. (2026) · Medical Journal of Cell Biology · doi:10.2478/acb-2026-0005
Glucagon-like peptide 1 receptor agonists in cardiovascular-kidney-metabolic syndrome: a review
Zhou, J., Zhang, N., Li, J., Qin, X., Kong, L., Bai, L., & Han, T. (2026) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2026.101481
Managing heart failure in the longer term
Ahmed, F. Z., Beezer, J., Fuat, A., Halliday, B. P., Ludman, A. J., Pellicori, P., Savage, H. O., Taylor, C. J., & Cleland, J. G. F. (2024) · Considerations in Medicine · doi:10.1136/conmed-2024-000013
“38 39 The implications of these findings are relevant, potentially heralding a paradigm shift in the management of HFpEF.”
Self-citationKusayev, J., Levy, Y., Weininger, D., Frishman, W. H., & Aronow, W. S. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000726
Windy City Breakthroughs: Highlights from the American Heart Association Scientific Sessions 2024
HAJDUCZOK, A. G., Stives, D., Fabbri, M., DONALD, E. M., Maning, J., & Mentz, R. J. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.11.006
Pharmakotherapie der chronischen Herzinsuffizienz
Oexner, R. R., & Frantz, S. (2026) · Kardiologie up2date · doi:10.1055/a-2701-0826
Adipositas und Herz: neue Medikamente und neue Strategien für Kardiologen
Hollstein, T. (2025) · Aktuelle Kardiologie · doi:10.1055/a-2606-7020
“Eine umfassende Aufklärung und Gegenstrategien etwa kleinere Mahlzeiten, langsame Aufdosierung oder spezielle Ernährungs-empfehlungen”
Lu, D., Li, N., Yuan, Z., & Gao, Y. (2026) · Clinical Obesity · doi:10.1111/cob.70112
Targeting the Cardiometabolic Axis: An Integrative Review on Therapeutic Advances
Duru, P., Tasouli-Drakou, V., Ramazani, N., Hartnett, S., Cyrus, T., & Tak, T. (2026) · International Journal of Angiology · doi:10.1055/a-2904-8884
“51 Moreover, patients on semaglutide showed greater improvement in symptoms, with a larger change in their KCCQ-CSS (16.6 points versus 8.7 points), as well as a reduction in CRP levels ( – 43.5% versus – 7.3%).”
InfluentialBhaduri, G., BHATTACHARYYA, S., Mukherjee, S., & Gokalani, R. A. (2026) · Acta Diabetologica · doi:10.1007/s00592-025-02636-7
Circadian mechanisms in heart failure: Cell-specific regulation and chrono-medicine
Cheng, S., Zhou, R., Zhang, Z., & Li, M. (2026) · Cell Insight · doi:10.1016/j.cellin.2026.100363
Metadata
- Authors
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., Melenovsky, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., Van der Meer, P., von Lewinski, D., Wolf, D., & Petrie, M. C.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) — both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Diabetes Research Centre, University of Leicester, and National Institute for Health and Care Research Leicester Biomedical Research Centre (M.D.), Leicester, the Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (F.Z.A.), and the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.) — all in the United Kingdom; the Department of Cardiovascular Medicine ...
- ORCID
- Kosiborod, Mikhail N.
- Borlaug, Barry A.
- Butler, Javed
- Davies, Melanie
- Hovingh, G. Kees
- Kitzman, Dalane W.
- Shah, Sanjiv J.
- Verma, Subodh
- Abhayaratna, Walter
- Ahmed, Fozia Z.
- Chopra, Vijay
- Ezekowitz, Justin
- Fu, Michael
- Ito, Hiroshi
- Lelonek, Małgorzata
- Merkely, Bela
- Núñez, Julio
- Perna, Eduardo
- Schou, Morten
- Senni, Michele
- Sharma, Kavita
- Wolf, Dennis
- Petrie, Mark C
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-21
- Volume
- 389
- Issue
- 12
- Pages
- 1069-1084
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4386154055
- Cited by
- 1,669
- References
- 41
- Citations by year
- 2026: 548 · 2025: 597 · 2024: 461 · 2023: 61
- FWCI
- 327.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, heart failure with preserved ejection fraction, obesity, weight loss, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, GLP-1 receptor agonists, heart failure events, body weight, symptom burden
- MeSH terms
- Semaglutide, Glucagon-Like Peptides, Heart Failure, Humans, Obesity, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.